Svb Leerink Reaffirms “Outperform” Rating for Relmada Therapeutics (NYSE:RLMD)

Relmada Therapeutics (NYSE:RLMD)‘s stock had its “outperform” rating restated by equities researchers at Svb Leerink in a report issued on Friday, Zacks.com reports.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions.

Recommended Story: Profit Margin

Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply